Papillary Breast Lesions: Diagnostic Challenges and Overview of Entities

Česká verze

Authors: Zuzana Slobodová
Authors place of work: Ústav klinické a molekulární patologie, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc
Published in the journal: Čes.-slov. Patol., 61, 2025, No. 4, p. 178-189
Category: Přehledový článek

Summary

Papillary breast lesions represent a morphologically and biologically diverse group of entities that include benign intraductal papillomas, papillomas with atypical ductal hyperplasia, with ductal or lobular carcinoma in situ, papillary ductal carcinoma in situ, encapsulated papillary carcinoma (with or without invasion), solid papillary carcinoma, and invasive papillary carcinoma. Accurate classification is often challenging particularly in core needle biopsies, and even in excision specimens can pose difficulties, especially for less experienced pathologists. This review summarizes the essential histological and immunohistochemical features of each lesion and highlights key diagnostic pitfalls and helpful clues in their differential diagnosis. While genetic testing is not routinely required for diagnostic purposes, recent studies have identified more or less distinct molecular alterations across the spectrum of papillary lesions. These findings may support future refinements in classification and understanding of these tumors.

Keywords:

papillary breast lesions – intraductal papilloma – encapsulated papillary carcinoma – solid papillary carcinoma

Zdroje

WHO Classification of Tumours Editorial Board. Breast Tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2019.
Hodorowicz-Zaniewska D, Szpor J, Basta P. Intraductal papilloma of the breast management. Ginekol Pol 2019; 90(2): 100-103.
Rakha EA, Ahmed MA, Ellis IO. Papillary carcinoma of the breast: diagnostic agreement and management implications. Histopathology 2016; 69(5): 862-870.
Tse GM, Tan PH, Lui PC. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 2007; 60(3): 315-320.
Ichihara S, Fujimoto T, Hashimoto K, Moritani S, Hasegawa M, Yokoi T. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. Pathol Int 2007; 57(3): 126-132.
Tse GM, Tan PH, Moriya T. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 2009; 62(5): 407-413.
Grin A, O‘Malley FP, Mulligan AM. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy. Am J Surg Pathol 2009; 33(11): 1615-1623.
Yanai H, Ishida M, Yoshikawa K, Tsuta K, Sekimoto M, Sugie T. Immunohistochemical analyses of the expression profiles of INSM1, ATRX, DAXX and DLL3 in solid papillary carcinomas of the breast. Oncol Lett 2022; 23(4): 137.
Agoumi M, Giambattista J, Hayes MM. Practical Considerations in Breast Papillary Lesions: A Review of the Literature. Arch Pathol Lab Med 2016; 140(8): 770-790.
Cserni G, Francz M, Járay B, et al. Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathol Oncol Res 2022; 28 : 1610373.
Amendoeira I, Apostolikas N, Bellocq JP, et al. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. (4th edn). Luxembourg: European Comission; 2006 : 219–311.
Kulka J, Madaras L, Floris G, Lax SF. Papillary lesions of the breast. Virchows Arch 2022; 480(1): 65-84.
Wei S. Papillary Lesions of the Breast: An Update. Arch Pathol Lab Med 2016; 140(7): 628-643.
Tramm T, Kim JY, Tavassoli FA. Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast. Am. J. Surg. Pathol 2011; 35(2); 202–211.
Rakha EA, Ellis IO. Diagnostic challenges in papillary lesions of the breast. Pathology 2018; 50(1): 100-110.
Schwartz CJ, Krings G. Salivary gland-like tumors of the breast: Histopathologic and genetic features with clinical implications. Semin Diagn Pathol 2024; 41(6): 272-284.
Boac BM, Centeno BA. Pleomorphic adenoma of the breast with cytologic atypia on cytopathology: A potential diagnostic pitfall and literature review. Diagn Cytopathol 2022; 50(5): 265-269.
Zhang X, Liu W, Hai T, Li F. Upgrade Rate and Predictive Factors for Breast Benign Intraductal Papilloma Diagnosed at Biopsy: A Meta-Analysis. Ann Surg Oncol 2021; 28(13): 8643-8650.
Corbin H, Bomeisl P, Amin AL, Marshall HN, Gilmore H, Harbhajanka A. Upgrade rates of intraductal papilloma with and without atypia diagnosed on core needle biopsy and clinicopathologic predictors. Hum Pathol 2022; 128 : 90-100.
de Boer M, Verschuur-Maes AHJ, Moelans C, van Diest PJ. Papillomatous breast lesions with atypical columnar cell features. J Clin Pathol 2023; 76(4): 228-233.
Mihara Y, Takahashi R, Mizuochi S, Yamaguchi R, Akiba J. Additional report: recurrence of intraductal papilloma with atypical ductal hyperplasia as solid papillary carcinoma. Med Mol Morphol 2025; 58(1): 87-90.
Mihara Y, Yamaguchi R, Takahashi R, Yano Y, Yano H. Intraductal papilloma with atypical ductal hyperplasia and neuroendocrine differentiation as a possible precursor lesion of solid papillary carcinoma. Med Mol Morphol 2023; 56(3): 227-232.
Min KW, Min SK, Kwon MJ, Seo J, Park HR, Kim LS. Extensive Lobular Carcinoma In Situ with Pagetoid Spread into Multiple Papillomas of the Breast. Breast J 2016; 22(6): 693-695.
Li JK, Xu YJ, Niu RL, et al. Atypical ductal hyperplasia diagnosed by US-guided core needle biopsy: clinical, pathological and US features associated with upgrading to malignancy. BMC Med Imaging 2025; 25(1): 168.
Ni Y, Tse GM. Papillary lesions of the breast review and practical issues. Semin Diagn Pathol 2022; 39(5): 344-354.
Bezić J, Smolić J, Bečić K. Dimorphic Invasive Breast Carcinoma with Tubulopapillary Features. International Journal of Surgical Pathology 2022; 31(7): 1314-1316.
Lefkowitz M, Lefkowitz W, Wargotz ES. Intraductal (intracystic) papillary carcinoma of the breast and its variants: a clinicopathological study of 77 cases. Hum Pathol 1994; 25(8): 802-809.
Collins LC, Schnitt SJ. Papillary lesions of the breast: selected diagnostic and management issues. Histopathology 2008; 52(1): 20-29.
Rakha EA, Quinn C. Controversies regarding encapsulated papillary carcinoma of the breast: an approach to evaluation and categorisation. Histopathology 2025; 86(4): 497-513.
Liu ZL, Zhang Q, Lu Q, Zhang C, Chen J, Dong YY, Liu LP. Clinical and imaging characteristics of encapsulated papillary carcinoma: a comparative analysis with intraductal papilloma. World J Surg Oncol 2025; 23(1): 244.
Taniguchi K, Yamasaki R, Kajiwara Y, Ichimura K, Yoshino T. A Case Report on Apocrine Encapsulated Papillary Carcinoma of the Breast with Frank Invasion: A Diagnostic Quandary. Int J Surg Pathol 2022; 30(8): 939-944.
Nomoto Y, Yoshinaka H, Ohi Y, et al. Apocrine papillary lesion: comparison of pathological findings from 22 years previously and the present. Breast Cancer 2019; 26(4): 524-528.
Liu X, Wu H, Teng L, Zhang H, Lu J, Liang Z. High-grade encapsulated papillary carcinoma of the breast is clinicopathologically distinct from low/intermediate-grade neoplasms in Chinese patients. Histol Histopathol 2019; 34(2): 137-147.
Changrong W, Zhibo Z, Jufeng G, Hongju Y, Feng Y, Jingjing X. Encapsulated Papillary Carcinoma of the Breast: A Review of Clinicopathologic Characteristics, Molecular Mechanisms, and Patient Management. Cancer Control 2024; 31 : 10732748241299071.
Hashmi AA, Iftikhar SN, Munawar S, Shah A, Irfan M, Ali J. Encapsulated Papillary Carcinoma of Breast: Clinicopathological Features and Prognostic Parameters. Cureus 2020; 12(10): e11282.
Jadhav T, Prasad SS, Guleria B, Tevatia MS, Guleria P. Solid papillary carcinoma of the breast. Autops Case Rep 2022; 12: e2021352.
Guo S, Wang Y, Rohr J, Fan C, Li Q, Li X, Wang Z. Solid papillary carcinoma of the breast: A special entity needs to be distinguished from conventional invasive carcinoma avoiding over-treatment. Breast 2016; 26 : 67 -⁠ 72.
Maeda I, Tajima S, Kanemaki Y, Tsugawa K, Takagi M. Use of immunohistochemical analysis of CK5/6, CK14, and CK34betaE12 in the differential diagnosis of solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia of the breast. SAGE Open Med 2018; 6 : 2050312118811542.
Sharma R, Thirunavukkarasu B, Elhence P, Vishnoi JR. Invasive solid papillary carcinoma with invasive lobular and invasive breast carcinoma, no special type: a rare association. BMJ Case Rep 2021; 14(5): e243628.
Tariq MU, Idress R, Qureshi MB, Kayani N. Solid papillary carcinoma of breast; a detailed clinicopathological study of 65 cases of an uncommon breast neoplasm with literature review. Breast J 2020; 26(2): 211-215.
Kudo N, Takano J, Kudoh S, Arima N, Ito T. INSM1 immunostaining in solid papillary carcinoma of the breast. Pathol Int 2021; 71(1): 51-59.
Christgen M, Bartels S, van Luttikhuizen JL, et al. Subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid-papillary carcinoma. J Pathol Clin Res 2017; 3(3): 191-202.
Koufopoulos N, Pateras IS, Gouloumis AR, et al. Diagnostically Challenging Subtypes of Invasive Lobular Carcinomas: How to Avoid Potential Diagnostic Pitfalls. Diagnostics (Basel) 2022; 12(11): 2658.
Huang K, Appiah L, Mishra A, Bagaria SP, Gabriel ME, Misra S. Clinicopathologic Characteristics and Prognosis of Invasive Papillary Carcinoma of the Breast. J Surg Res 2021; 261 : 105-112.
Chen S, Wang J, Yang L, Ji M, Chen S. Comparative analysis of clinicopathologic characteristics and molecular subtypes of invasive papillary carcinoma of the breast and invasive ductal carcinoma: results from SEER database. J BUON 2021; 26(5): 1991-2002.
Yang YL, Liu BB, Zhang X, Fu L. Invasive Micropapillary Carcinoma of the Breast: An Update. Arch Pathol Lab Med 2016; 140(8): 799-805.
Abe N, Matsumoto H, Motonari T, Nakada N, Zaha H, Tan PH, Yoshimi N. Invasive papillary carcinoma of the breast with an unusual immunophenotype. Pathol Int 2019; 69(3): 183-185.
Toss MS, Billingham K, Egbuniwe IU, Moreno F, Abass A, Rakha EA. Breast Tumours Resembling the Tall Cell Variant of Thyroid Papillary Carcinoma: Are They Part of the Papillary Carcinoma Spectrum or a Distinct Entity? Pathobiology 2019; 86(2-3): 83-91.
Kajo K, Ducár M, Dzuracký J, et al. Karcinóm prsníka z vysokých buniek s obrátenou polaritou opis troch prípadov s prehľadom literatúry. Cesk Patol 2023; 59(3): 132-138.
Kader T, Elder K, Zethoven M, et al. The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. NPJ Breast Cancer 2020; 6 : 9.
Yoshida M, Tsuda H, Yamamoto S, Kinoshita T, Akashi-Tanaka S, Hojo T, Fukutomi T. Loss of heterozygosity on chromosome 16q suggests malignancy in core needle biopsy specimens of intraductal papillary breast lesions. Virchows Arch 2012; 460(5): 497-504.
Schwartz CJ, Boroujeni AM, Khodadadi-Jamayran A, et al. Molecular analysis of encapsulated papillary carcinoma of the breast with and without invasion. Hum Pathol 2021; 111 : 67-74.
Weigelt MA, Sciallis AP, McIntire PJ, Ko JS, Billings SD, Ronen S. Nipple Adenoma: Clinicopathologic Characterization of 50 Cases. Am J Surg Pathol 2023; 47(8): 926-932.
Moatasim A, Mamoon N. Primary Breast Mucinous Cystadenocarcinoma and Review of Literature. Cureus. 2022; 14(3): e23098.
Shui R, Cheng Y, Bai Q, Yang W. Secretory breast carcinoma with a papillary-predominant pattern: an unusual morphological variant. Histopathology 2017; 71(3): 488-493.